Follow Us On :
About Us
Company Profile
From the Chairman's Desk
Vision, Core Values
Milestones
Board of Directors
Management Profile
Mergers & Acquisitions
International Operations
Strategy
Subsidiaries
Bell, Sons & Co. (Druggists) Ltd.
Nova Pharmaceuticals Australasia Pty Ltd.
Relonchem Limited
Time Cap Labs, Inc.
R & D Capabilities
Quality Policy
World Wide Operations
Formulation Business
Overview
Markets
USA
Europe
South East Asia
Africa
Russia & CIS
Latin America
Australasia
Manufacturing Facilities
Locations (Goa/ Southport - UK)
R & D
CRAMS
Out Licensing
Business Development
Investor Relations
General Information & Investor Contact
General Information
Composition of Board & Committees
Investor Contact
Materiality of Information
Corporate Announcements
Financial Results
Quarterly Results
Annual Reports
Subsidiary Accounts
Investors Presentation
Investors Meet
Compliances
Shareholding Pattern
Corporate Governance
Codes & Policies
Independent Directors
Investors Grievance Report
Shareholders Meeting
Unclaimed Dividend
Shares Liable for Transfer to IEPF
CSR Activities
Others Disclosures
Forms
Newspaper Advertisement
Press Release
PD
Industry Overview
Health and Illness
Oncology And Critical Care
The Disorders Of The Mind And Nerves
Neurological Disorder
Mental Disorders
Skin Infections And Ulcers
Gastro - Intestinal Disorders (GI)
Cough Remedies
Women's Health
Bacterial Infections And Its Treatment
Blog
Careers
Overview
Values
Life at Marksans
Adverse Event
Contact Us
Open Menu
Home
About Us
Company Profile
From the Chairman's Desk
Vision, Core Values
Milestones
Board of Directors
Management Profile
Mergers & Acquisitions
International Operations
Strategy
Subsidiaries
Bell, Sons & Co. (Druggists) Ltd.
Nova Pharmaceuticals Australasia Pty Ltd.
Relonchem Limited
Time Cap Labs, Inc.
R & D Capabilities
Quality Policy
World Wide Operations
Formulation Business
Overview
Markets
USA
Europe
South East Asia
Africa
Russia & CIS
Latin America
Manufacturing Facilities
Locations (Goa/ Southport - UK)
R & D
CRAMS
Out Licensing
Business Development
Investor Relations
General Information & Investor Contact
General Information
Composition of Board & Committees
Investor Contact
Materiality of Information
Corporate Announcements
Financial Results
Quarterly Results
Annual Reports
Subsidiary Accounts
Investors Presentation
Investors Meet
Compliances
Shareholding Pattern
Corporate Governance
Codes & Policies
Independent Directors
Investors Grievance Report
Shareholders Meeting
Unclaimed Dividend
Shares Liable for Transfer to IEPF
CSR Activities
Others Disclosures
Forms
Newspaper Advertisement
Press Release
PD
Industry Overview
Health and Illness
Oncology And Critical Care
The Disorders Of The Mind And Nerves
Neurological Disorder
Mental Disorders
Skin Infections And Ulcers
Gastro - Intestinal Disorders (GI)
Cough Remedies
Women's Health
Bacterial Infections And Its Treatment
Blog
Careers
Overview
Values
Life at Marksans
Adverse Event
Contact Us
Site Map
Investor Relations
General Information & Investor Contact
Corporate Announcements
Financial Results
Quarterly Results
Annual Reports
Subsidiary Accounts
Investors Presentation
Investors Meet
Compliances
Press Release
PD
Home
Investor Relations
Financial Results
Investors Meet
2024
2023
2022
2021
Q1FY24 Earnings Conference Call Transcript
Q1FY24 Conference Call
Your browser does not support the audio element.
Q4FY23 Earnings Conference Call Transcript
Q4FY23 Conference Call
Your browser does not support the audio element.
Q3 FY23 Earnings Conference Call Transcript
Q3FY23 Conference Call
Your browser does not support the audio element.
Q2 FY23 Earnings Conference Call Transcript
Q2 FY23 & H1FY23 Conference Call
Your browser does not support the audio element.
Q1 FY23 Earnings Conference Call Transcript
Q1 FY23 Conference Call
Your browser does not support the audio element.
Q4 & FY22 Conference Call
Your browser does not support the audio element.
Q4 & FY22 Conference Call - Transcript
February 2022
November 2021
© Copyright 2013 Marksans Pharma.
